105 126

Cited 9 times in

A validated single-cell-based strategy to identify diagnostic and therapeutic targets in complex diseases

Authors
 Danuta R. Gawel  ;  Jordi Serra-Musach  ;  Sandra Lilja  ;  Jesper Aagesen  ;  Alex Arenas  ;  Bengt Asking  ;  Malin Bengnér  ;  Janne Björkander  ;  Sophie Biggs  ;  Jan Ernerudh  ;  Henrik Hjortswang  ;  Jan-Erik Karlsson  ;  Mattias Köpsen  ;  Eun Jung Lee  ;  Antonio Lentini  ;  Xinxiu Li  ;  Mattias Magnusson  ;  David Martínez-Enguita  ;  Andreas Matussek  ;  Colm E. Nestor  ;  Samuel Schäfer  ;  Oliver Seifert  ;  Ceylan Sonmez  ;  Henrik Stjernman  ;  Andreas Tjärnberg  ;  Simon Wu  ;  Karin Åkesson  ;  Alex K. Shalek  ;  Margaretha Stenmarker  ;  Huan Zhang  ;  Mika Gustafsson  ;  Mikael Benson 
Citation
 Genome Medicine, Vol.11(1) : 47, 2019 
Journal Title
 Genome Medicine 
Issue Date
2019
Keywords
Biomarker and drug discovery ; Network tools ; scRNA-seq
Abstract
BACKGROUND: Genomic medicine has paved the way for identifying biomarkers and therapeutically actionable targets for complex diseases, but is complicated by the involvement of thousands of variably expressed genes across multiple cell types. Single-cell RNA-sequencing study (scRNA-seq) allows the characterization of such complex changes in whole organs. METHODS: The study is based on applying network tools to organize and analyze scRNA-seq data from a mouse model of arthritis and human rheumatoid arthritis, in order to find diagnostic biomarkers and therapeutic targets. Diagnostic validation studies were performed using expression profiling data and potential protein biomarkers from prospective clinical studies of 13 diseases. A candidate drug was examined by a treatment study of a mouse model of arthritis, using phenotypic, immunohistochemical, and cellular analyses as read-outs. RESULTS: We performed the first systematic analysis of pathways, potential biomarkers, and drug targets in scRNA-seq data from a complex disease, starting with inflamed joints and lymph nodes from a mouse model of arthritis. We found the involvement of hundreds of pathways, biomarkers, and drug targets that differed greatly between cell types. Analyses of scRNA-seq and GWAS data from human rheumatoid arthritis (RA) supported a similar dispersion of pathogenic mechanisms in different cell types. Thus, systems-level approaches to prioritize biomarkers and drugs are needed. Here, we present a prioritization strategy that is based on constructing network models of disease-associated cell types and interactions using scRNA-seq data from our mouse model of arthritis, as well as human RA, which we term multicellular disease models (MCDMs). We find that the network centrality of MCDM cell types correlates with the enrichment of genes harboring genetic variants associated with RA and thus could potentially be used to prioritize cell types and genes for diagnostics and therapeutics. We validated this hypothesis in a large-scale study of patients with 13 different autoimmune, allergic, infectious, malignant, endocrine, metabolic, and cardiovascular diseases, as well as a therapeutic study of the mouse arthritis model. CONCLUSIONS: Overall, our results support that our strategy has the potential to help prioritize diagnostic and therapeutic targets in human disease.
Files in This Item:
T201903604.pdf Download
DOI
10.1186/s13073-019-0657-3
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Eun Jung(이은정) ORCID logo https://orcid.org/0000-0002-0454-4510
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/171460
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links